Edesa Biotech (EDSA) Other Non Operating Income (2013 - 2026)
Edesa Biotech (EDSA) posted Other Non Operating Income of -$8758.0 for Q4 2025, down 165.8% sequentially from -$3295.0 in Q1 2025, and up 59.12% YoY from -$5503.9 in Q4 2024.
Edesa Biotech (EDSA) Other Non Operating Income (2013 - 2026) Analysis & Trends
Edesa Biotech has reported Other Non Operating Income for 13 years, with the latest figure at -$8758.0 in Q4 2025.
- Quarterly Other Non Operating Income rose 59.12% year-over-year to -$8758.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$12053.0 (up 88.1% YoY) and the FY2024 annual result came in at -$58200.0, changed N/A from the prior year.
- Other Non Operating Income eased to -$8758.0 in Q4 2025 per EDSA's latest filing, from -$3295.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $10.3 million in Q3 2021 and troughed at -$72966.0 in Q3 2024.
- A 5-year average of $638240.5 and a median of -$4086.0 in 2021 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2021 and 2024: Other Non Operating Income jumped 187828.62% in 2021, then sank 659.21% in 2024.
- Over 5 years, Other Non Operating Income stood at -$3331.0 in 2021, then sank by 78.35% to -$5941.0 in 2022, then soared by 52.5% to -$2822.0 in 2023, then tumbled by 659.21% to -$21425.0 in 2024, then jumped by 59.12% to -$8758.0 in 2025.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$8758.0, -$3295.0, and -$21425.0 for Q4 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Edesa Biotech | 40.44 Mn | 40.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4,295.00 |
| Dec 31, 2025 | -8,758.00 |
| Mar 31, 2025 | -3,295.00 |
| Dec 31, 2024 | -21,425.00 |
| Sep 30, 2024 | -72,966.00 |
| Jun 30, 2024 | -4,841.00 |
| Mar 31, 2024 | -2,018.00 |
| Dec 31, 2023 | -2,822.00 |
| Mar 31, 2023 | -8,686.00 |
| Dec 31, 2022 | -5,941.00 |
| Sep 30, 2022 | -13,737.00 |
| Jun 30, 2022 | -7,013.00 |
| Mar 31, 2022 | 2,967.00 |
| Dec 31, 2021 | -3,331.00 |
| Sep 30, 2021 | 10.28 Mn |
| Jun 30, 2021 | 3,663.00 |
| Mar 31, 2021 | 80,032.00 |
| Dec 31, 2020 | -24,732.00 |
| Sep 30, 2020 | -5,476.00 |
| Jun 30, 2020 | -692.00 |